



Original Investigation | Pediatrics

Effect of Vitamin D₃ Supplementation in the First 2 Years of Life on Psychiatric Symptoms at Ages 6 to 8 Years

A Randomized Clinical Trial

Samuel Sandboge, MD, PhD; Katri Räikkönen, PhD; Marius Lahti-Pulkkinen, PhD; Helena Hauta-alus, PhD; Elisa Holmlund-Suila, MD, PhD; Polina Girchenko, PhD; Eero Kajantie, MD, PhD; Outi Mäkitie, MD, PhD; Sture Andersson, MD, PhD; Kati Heinonen, PhD

Abstract

IMPORTANCE Vitamin D is associated with neurodevelopment, but causality, critical windows, and potentials for modification remain unknown.

OBJECTIVE To determine the impact of high-dose (1200 IU) vs standard-dose (400 IU) vitamin D₃ supplementation during the first 2 years on psychiatric symptoms at ages 6 to 8 years and whether the impact is different in children with lower vs higher maternal vitamin D₃ levels; lower vs higher levels were defined as 25-hydroxyvitamin D (25[OH]D) less than 30 ng/mL vs 30 ng/mL or greater.

DESIGN, SETTING, AND PARTICIPANTS This study was a long-term follow-up of the double-blind randomized clinical trial (RCT) Vitamin D Intervention in Infants (VIDI) conducted at a single center in Helsinki, Finland, at 60 degrees north latitude. Recruitment for VIDI took place in 2013 to 2014. Follow-up data for secondary data analysis were collected 2020 to 2021. VIDI originally included 987 term-born infants; 546 of these individuals participated in the follow-up at ages 6 to 8 years, among whom 346 individuals had data on parent-reported psychiatric symptoms. Data were analyzed from June 2022 to March 2023.

INTERVENTIONS There were 169 infants randomized to receive 400-IU and 177 infants randomized to receive 1200-IU oral vitamin D₃ supplementation daily from ages 2 weeks to 24 months.

MAIN OUTCOMES AND MEASURES Primary outcomes were internalizing, externalizing, and total problems scores, with clinically significant problems defined as *T* scores of 64 or greater in the Child Behavior Checklist questionnaire.

RESULTS Among 346 participants (164 females [47.4%]; mean [SD] age, 7.1 [0.4] years), the vitamin D₃ dose was 400 IU for 169 participants and 1200 IU for 177 participants. Clinically significant internalizing problems occurred in 10 participants in the 1200-IU group (5.6% prevalence) compared with 20 participants (11.8%) in the 400-IU group (odds ratio, 0.40; 95% CI, 0.17-0.94; *P* = .04) after adjustment for sex, birth season, maternal depressive symptoms at birth, and parental single status at follow-up. In a post hoc subgroup analysis, 48 children in the 400-IU group with maternal 25(OH)D concentrations less than 30 ng/mL had higher internalizing problems scores compared with children in the 1200-IU group, including 44 children with maternal 25(OH)D concentrations below 30 ng/mL (adjusted mean difference, 0.49; 95% CI, 0.09-0.89; *P* = .02) and 91 children with maternal concentrations above 30 ng/mL (adjusted mean difference, 0.37; 95% CI, 0.03-0.72; *P* = .04). Groups did not differ in externalizing or total problems.

(continued)

Key Points

Question Does higher daily vitamin D₃ supplementation up to age 2 years decrease the risk of psychiatric symptoms at ages 6 to 8 years compared with the standard recommended dose?

Findings In this secondary analysis of a randomized clinical trial including 346 children, those randomized to higher vitamin D₃ supplementation were less likely to have clinically significant internalizing problems.

Meaning This study found that higher than standard vitamin D₃ supplementation up to age 2 years decreased the risk for internalizing problems in later childhood.

+ [Visual Abstract](#)

+ [Supplemental content](#)

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Abstract (continued)

CONCLUSIONS AND RELEVANCE This randomized clinical trial found that higher-than-standard vitamin D₃ supplementation in the first 2 years decreased risk of internalizing problems at ages 6 to 8 years.

TRIAL REGISTRATION ClinicalTrials.gov Identifiers: [NCT01723852](https://clinicaltrials.gov/ct2/show/study/NCT01723852) (VIDI) and [NCT04302987](https://clinicaltrials.gov/ct2/show/study/NCT04302987) (VIDI2)

JAMA Network Open. 2023;6(5):e2314319. doi:10.1001/jamanetworkopen.2023.14319

Introduction

Vitamin D insufficiency and deficiency are estimated to occur among almost half and more than one-tenth of the global population, respectively, across all ages.^{1,2} In addition to its well-known role in skeletal health, vitamin D also plays a role in neurodevelopment. Receptors and metabolizing enzymes for vitamin D are present in various areas of the human brain,³ and experimental animal studies have linked vitamin D deficiency to abnormal brain development.⁴

Approximately one-eighth of children in high-income countries have mental disorders,⁵ and much is still unknown regarding their etiology. Results from previous studies, which were primarily observational,^{6,7} suggested that lower childhood vitamin D levels, measured as serum 25-hydroxyvitamin D (25[OH]D), were associated with autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). Lower childhood vitamin D levels have also been associated with increased levels of depressive symptoms⁸ and internalizing and externalizing problems⁹ later in childhood. Causality, however, can be verified only using randomized clinical trials (RCTs). Our 2021 publication of a part of the double-blind interventional RCT Vitamin D Intervention in Infants (VIDI) study¹⁰ did not show benefits of a higher-than-standard vitamin D₃ supplementation (1200 IU) between ages 2 weeks and 2 years compared with standard recommended supplementation (400 IU) on internalizing, externalizing, or dysregulation problems; competencies; or developmental milestones up to age 2 years. Conversely, the study found a potential small negative impact of higher-than-standard supplementation on externalizing problems. Behavioral and psychiatric problems may not be fully manifested during the early years but may become more evident when environmental demands increase.¹¹ For example, the estimated earliest peak age at onset for anxiety and fear-related disorders is 5.5 years.¹¹ Accordingly, the primary aim of this follow-up study was to build on our previous study and extend the inquiry to childhood psychiatric symptoms at ages 6 to 8 years. This period is characterized by increased demand for self-regulating skills, important in mitigating potential internalizing and externalizing problems, combined with a still-developing prefrontal cortex.¹²

Lower 25(OH)D levels in pregnancy have been associated with unfavorable neurobehavioral and mental health outcomes in offspring, including negative affectivity in infancy,¹³ attention-deficit/hyperactivity disorder,^{14,15} autism spectrum disorder,¹⁶ and depression.¹⁷ Therefore, our secondary aim was to explore whether a higher-than-standard childhood vitamin D₃ supplementation modified the potential impact of maternal 25(OH)D levels during pregnancy on child mental health outcomes.

Methods

Participating children's parents signed informed consent forms at recruitment and at the 6 to 8-year follow-up for this RCT secondary analysis. Children gave written consent to participate at the 6 to 8-year follow-up. The study was approved by the ethics committee at the Hospital District of Helsinki and Uusimaa and registered with ClinicalTrials.gov ([NCT01723852](https://clinicaltrials.gov/ct2/show/study/NCT01723852) [VIDI] and [NCT04302987](https://clinicaltrials.gov/ct2/show/study/NCT04302987) [VIDI2]); it follows the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.


Study Design and Participants

The VIDJ study (see trial protocol in Supplement 1) is a double-blind, interventional RCT described previously in detail.¹⁸⁻²⁰ The study originally comprised 987 families (492 female and 495 male infants) recruited from the Kätilöopisto Maternity Hospital in Helsinki, Finland, at 60 degrees north latitude between January 1, 2013, and June 30, 2014. All infants had Northern European ancestry. Infants were randomized to receive oral vitamin D₃ supplementation at 400 IU (10 µg; 495 individuals) or 1200 IU (30 µg; 492 individuals) from ages 2 weeks to 2 years. Of recruited families, 12 did not meet inclusion criteria (Figure). Randomization was performed in blocks of 50 infants by a pharmacist at Helsinki University Hospital without relation to the study.¹⁸ Supplements were prepared by Orion Pharmaceuticals, and both groups received 5 drops daily. Parents received information of group membership after the 2-year intervention concluded. Self-administered questionnaires were used to collect information regarding parental health, lifestyle, and demographics. Information on gestation, delivery, and child demographics was derived from hospital records. Maternal serum samples were collected during routine maternity clinic follow-up visits at 6 to 27 weeks of gestation (mean [SD] gestation time, 11.3 [1.9] weeks) and stored in the Finnish Maternity Cohort serum bank as organized by the Finnish Institute for Health and Welfare. Samples were used to analyze maternal 25(OH)D concentrations.

Follow-up at 6 to 8 Years

The follow-up study was initiated in November 2019; we invited 817 families who remained in the original VIDJ study until completion of the intervention at age 2 years of the child and had available home address info to participate. Of 546 families who participated in the follow-up study (55.3% of the original study population), 456 families completed online questionnaires regarding psychological and cognitive outcomes between September 2020 and May 2021. Personnel conducting follow-up were blinded to group membership. There was 1 participant excluded owing to diagnosis of a rare genetic disorder. The population of this long-term follow-up study consisted of 346 children whose parents completed the Child Behavior Checklist (CBCL) questionnaire (63.4% of those in the follow-up study); of the original 400-IU group, 169 children (34.6%) were included, and of the original 1200-IU group, 177 children (36.4%) were included. These children had somewhat more

Figure. Flowchart of Study Enrollment, Allocation, and Follow-up



CBCL indicates Childhood Behavior Checklist.

beneficial baseline characteristics regarding breastfeeding duration, maternal 25(OH)D level, smoking status, and parental education level compared with nonparticipants (eTable 1 in Supplement 2).

Biochemical Analysis

Serum 25(OH)D concentrations were analyzed at the Pediatric Research Centre, University of Helsinki, using a fully automated IDS-iSYS immunoassay system with chemiluminescence detection (Immunodiagnosics System). Biochemical analyses are described in detail in the eAppendix in Supplement 2 and elsewhere.^{18,19} In this study, 30 ng/mL (to convert to nanomoles per liter, multiply by 2.496) was used as the cutoff point for maternal 25(OH)D concentration. This was previously suggested as a cutoff point for suboptimal 25(OH)D levels.²¹

Outcome Measures

Childhood psychiatric symptoms were assessed at a mean (SD; range) age of 7.1 years (0.4; 6.3-8.2) years using CBCL, a standardized questionnaire comprising 113 items scored using a 3-point Likert scale (0 = absent; 1 = occurs sometimes; 2 = occurs often).²² Parent-reported questionnaires were used to calculate composite scores of internalizing, externalizing, and total problems (Cronbach α was 0.81, 0.89, and 0.93, respectively). Achenbach System of Empirically Based Assessment (ASEBA-PC) software version 3.0.136.0 (T.M. Achenbach) was used to convert raw scores to age and sex-standardized *T* scores; *T* scores of 64 or greater are considered to reflect clinically significant internalizing, externalizing, and total problems. We used *Z* scores of square root-transformed raw scores (0 = mean; 1 = 1 SD) and dichotomized *T* scores for internalizing, externalizing, and total scores as outcome measurements.

Covariates

Potential covariates were assessed based on known association with childhood neurodevelopment or vitamin D₃ levels. They were child age at CBCL assessment,²² child sex,²³ maternal 25(OH)D level,¹³⁻¹⁷ birth season,^{24,25} gestational duration,²⁶ maternal age at delivery,²⁷ breastfeeding duration,²⁸ parental educational level,²⁹ parental single status at follow-up,³⁰ maternal smoking status,³¹ and maternal depressive symptoms assessed at the maternity ward after childbirth³² (eAppendix in Supplement 2).

Statistical Analysis

Longitudinal secondary data analyses followed the intention-to-treat principle; 2-tailed independent-sample *t* tests and Pearson χ^2 tests were used to compare follow-up characteristics between intervention groups. Differences between groups in psychiatric problems were assessed using linear and logistic regression analysis. Results are presented without adjustment (model 1) and after adjustment for sex, maternal depressive symptoms at birth, birth season, and parental single status at follow-up (model 2). Model 2 covariates were associated with at least 1 psychiatric problems score ($P < .05$) or differed significantly in parental single status between supplementation groups. No other assessed potential covariates were associated with outcome variables or group membership and thus were not included in analyses (eTable 2 in Supplement 2). Comparing supplementation groups with α set at .05, we had a power of 0.80 to exclude or confirm effect sizes greater than 0.30 in mean difference (MD) for continuous variables and odds ratios (ORs) smaller than 0.42 in dichotomous variables. The potential impact of attrition bias was tested using inverse probability weighting estimation. In supplemental analyses, we tested associations of 1-year and 2-year 25(OH)D levels with psychiatric outcomes using regression analyses presented previously.

To test the potential interaction between prenatal 25(OH)D level and supplementation degree, children were grouped by maternal pregnancy 25(OH)D level. A 30-ng/mL cutoff point was selected a priori based on previous studies.²¹ Initial analyses testing for interaction between intervention group status and the dichotomized maternal 25(OH)D concentration variable did not show

interactions at the $P < .05$ level (eAppendix in Supplement 2). However, exploratory post hoc linear and logistic regression analyses were conducted with adjustments as presented previously to examine differences in psychiatric problems among 4 subgroups created based on intervention group status and maternal 25(OH)D concentration. For reference groups, we first used the group with 400-IU supplementation and maternal 25(OH)D levels less than 30 ng/mL and then the group with 1200-IU supplementation and maternal 25(OH)D levels of 30 ng/mL or greater.

Analyses were conducted with sexes combined. Additional information on study characteristics stratified by sex and sex × intervention group interaction analysis is given in the eAppendix and eTables 3 and 4 in Supplement 2. Statistical analyses were performed using SPSS statistical software version 28 (IBM) and Stata statistical software version 17 (StataCorp). Data were analyzed from June 2022 to March 2023.

Results

Characteristics

The study population comprised 346 children (164 females [47.4%]; mean [SD] age at follow-up, 7.1 [0.4] years), including 169 children (80 females [47.3%]) in the 400-IU and 177 children (84 females [47.5%]) in the 1200-IU supplementation group. **Table 1** presents baseline characteristics. Concentrations of 25(OH)D were significantly higher in the 1200-IU group compared with the 400-IU group at 1 year (MD, 13.2 ng/mL; 95% CI, 11.0 to 15.4 ng/mL; $P < .001$) and 2 years (MD, 12.7 ng/mL; 95% CI, 10.7 to 14.6 ng/mL; $P < .001$) (**Table 2**). Differences between groups were of the same magnitude as those seen for the original study population at 1 year (805 individuals) and 2 year (814 individuals) follow-up.¹⁸ In attrition analysis, there were no differences in externalizing or internalizing behavior at 2 years between participants in this study and nonparticipants with 2-year follow-up data (eAppendix in Supplement 2).

Table 1. Baseline Characteristics by Intervention Group

Characteristic	Families (N = 346)			
	Total with data, No.	400-IU vitamin D (n = 169) No. (%)	Total with data, No.	1200-IU vitamin D (n = 177) No. (%)
Child				
Sex				
Female		80 (47.3)		84 (47.5)
Male	169	89 (52.7)	177	93 (52.5)
Gestational length, mean (SD), d	169	280.4 (7.8)	177	281.2 (7.3)
Season of birth				
Winter		28 (16.6)		29 (16.4)
Spring		67 (39.6)		62 (35.0)
Summer	169	39 (23.1)	177	49 (27.7)
Autumn		35 (20.7)		37 (20.9)
Parents				
Mother				
Age at delivery, mean (SD), y	168	31.4 (4.0)	177	31.4 (4.3)
Smoking at childbirth	168	19 (11.3)	173	20 (11.6)
Pregnancy 25(OH)D concentration				
Mean (SD), ng/mL	143	33.7 (9.1)	148	33.4 (7.9)
<30 ng/mL	143	49 (29.0)	148	47 (26.6)
High educational level ^a	145	123 (84.8)	148	122 (82.4)
Depressive symptoms at childbirth, median (IQR), score ^b	155	11.0 (8.0-16.0)	163	10.0 (8.0-15.0)
CES-D score ≥16 ^c	155	39 (25.2)	163	33 (19.6)
Father with high educational level	143	99 (69.2)	144	99 (68.8)

Abbreviations: 25(OH)D, serum 25-hydroxyvitamin D; CES-D, Center for Epidemiological Studies Depression Scale.

SI conversion factor: To convert 25(OH)D to nanomoles per liter, multiply by 2.496.

^a Parental education was categorized from 1 (comprehensive school) to 6 (university degree) and dichotomized into 2 levels: low (less than a bachelor's degree) and high (bachelor's degree or higher).

^b Depressive symptoms assessed using the CES-D.

^c Scores of 16 or greater indicate a risk of clinical depression.

Vitamin D₃ Supplementation During Early Childhood and Psychiatric Problems at Ages 6 to 8 Years

There were 20 children (11.8%) in the 400-IU group and 10 children (5.6%) in the 1200-IU group with clinically significant internalizing problems ($P = .04$). The corresponding numbers for externalizing and total problems were 16 children (9.5%) vs 16 children (9.0%) ($P = .83$) and 9 children (5.3%) vs 8 children (4.5%) ($P = .90$), respectively (Table 2). The OR for clinically significant internalizing problems was 0.40 (95% CI, 0.17-0.94; $P = .04$) after adjustment for sex, birth season, maternal depressive symptoms at birth, and parental single status at follow-up. Results remained significant after correction for attrition bias. We conducted sensitivity analyses by repeating model 1 analyses and restricting the sample size to 318 children with available CES-D scores. Additionally, model 2 analyses were repeated using means substitution for 28 children missing CES-D scores to retain the entire sample in the analyses. Sensitivity analysis results were in line with primary results (eAppendix in Supplement 2). No effect of supplementation was found for externalizing (OR, 0.89; 95% CI, 0.42-1.91; $P = .77$) or total (OR, 0.81; 95% CI, 0.29-2.23; $P = .68$) problems (Table 3).

Table 3 presents MDs for Z scores of square root-transformed internalizing (−0.20; 95% CI, −0.41 to 0.01; $P = .07$), externalizing (0.01; 95% CI, −0.21 to 0.22; $P = .94$), and total (−0.08; 95% CI, −0.29 to 0.14; $P = .48$) problem scores. Score distributions are presented in the eFigure in Supplement 2.

Table 2. Follow-up Characteristics by Intervention Group

Characteristic	Families (N = 346)				MD (95% CI)	P value ^a
	Total with data, No.	400-IU vitamin D (n = 169) No. (%)	Total with data, No.	1200-IU vitamin D (n = 177) No. (%)		
At 12-mo follow-up						
Length of breastfeeding, mean (SD), mo	167	11.3 (5.7)	177	11.0 (5.5)	−0.3 (−1.5 to 0.9)	.59
25(OH)D concentration						
Mean (SD), ng/mL	160	34.4 (8.0)	164	47.6 (11.6)	13.2 (11.0 to 15.4)	<.001
<30 ng/mL	160	55 (34.4)	164	4 (2.4)	NA	<.001
At 24-mo follow-up						
25(OH)D concentration						
Mean (SD), ng/mL	168	35.5 (8.0)	175	48.1 (10.3)	12.7 (10.7 to 14.6)	<.001
<30 ng/mL	168	47 (30.0)	175	6 (3.4)	NA	<.001
At 6-8-y follow-up						
Age, mean (SD), y	169	7.2 (0.5)	177	7.1 (0.4)	−0.03 (−0.1 to 0.1)	.56
CBCL raw score, median (IQR)						
Internalizing problems		5.0 (2.0-8.0)		4.0 (2.0-7.0)	NA	.14
Externalizing problems	169	5.0 (2.0-10.0)	177	5.0 (3.0-9.0)	NA	.95
Total problems		20.0 (11.0-30.0)		20.0 (10.0-29.0)	NA	.71
CBCL T score, mean (SD) ^b						
Internalizing problems		51.0 (9.2)		49.5 (0.7)	−1.5 (−3.4 to 0.4)	.13
Externalizing problems	169	50.9 (8.8)	177	51.1 (9.0)	0.2 (−1.7 to 2.1)	.82
Total problems		49.8 (8.5)		49.4 (9.0)	−0.4 (−2.2 to 1.5)	.69
Clinically significant problems						
Internalizing problems		20 (11.8)		10 (5.6)	NA	.04
Externalizing problems	169	16 (9.5)	177	16 (9.0)	NA	.83
Total problems		9 (5.3)		8 (4.5)	NA	.90
Parent single at follow-up	146	16 (11.0)	153	7 (4.6)	NA	.04

Abbreviations: 25(OH)D, serum 25-hydroxyvitamin D; CBCL, Childhood Behavior Checklist; MD, mean difference; NA, not applicable.

SI conversion factor: To convert 25(OH)D to nanomoles per liter, multiply by 2.496.

^a P values calculated using χ^2 test for proportions, Mann-Whitney U test for medians, t test for means (2-sided P values and equal variance not assumed), and linear regression (with maternal 25[OH]D level <30 ng/mL and 400-IU group as the reference).

^b CBCL raw scores converted to T scores and dichotomized. A T score of 64 or greater is considered to reflect clinically significant problems.

Levels of 25(OH)D at 1 and 2 Years and Psychiatric Problems at Ages 6 to 8 Years

Higher 25(OH)D levels at ages 1 and 2 years resulted in lower risk for clinically significant internalizing problems (1 year: OR, 0.93; 95% CI, 0.90 to 0.97; *P* = .001; 2 years: OR, 0.95; 95% CI, 0.91 to 0.98; *P* = .01) and lower internalizing problem scores (1 year: MD, -0.010; 95% CI, -0.019 to -0.001; *P* = .04; 2 years: MD, -0.012; 95% CI, -0.021 to -0.002; *P* = .02) in the unadjusted model (eTable 5 in Supplement 2). After adjustment, the effect of 1-year 25(OH)D levels was attenuated for internalizing problem scores but remained for clinically significant internalizing problems (OR 0.94; 95% CI, 0.89 to 0.98; *P* = .01); the effect remained at 2 years for both outcomes after adjustment (internalizing problem score: MD, -0.011; 95% CI, -0.021 to -0.002; *P* = .02; internalizing problems: OR, -0.95; 95% CI, 0.91 to 0.99; *P* = .01). There was no effect of child 25(OH)D levels on externalizing or total problems.

Maternal Vitamin D₃, Early Childhood Supplementation, and Psychiatric Problems at Ages 6 to 8 Years

Among 291 families with data on maternal 25(OH)D levels, there were 96 children whose mothers had levels less than 30 ng/mL (33.0%) compared with 208 of 517 nonparticipating families with these data (40.2%). We found no effect of maternal 25(OH)D levels on child psychiatric problems (eTable 2 in Supplement 2). The proportion of children with clinically significant problems for each of 4 maternal 25(OH)D and infant vitamin D₃ supplementation dose subgroups is given in eTable 6 in Supplement 2. The risk of clinically significant internalizing problems was significantly lower among 91 children in the 1200-IU group with maternal 25(OH)D levels of 30 ng/mL or greater compared with 44 children in the 400-IU group with maternal 25(OH)D levels less than 30 ng/mL (adjusted OR, 0.21; 95% CI, 0.06-0.78; *P* = .02) (Table 4).

In a post hoc subgroup analysis, 48 children in the 400-IU group with maternal 25(OH)D concentrations less than 30 ng/mL had higher internalizing problems scores compared with children in the 1200-IU group, including 44 children whose mothers had 25(OH)D concentrations below (adjusted MD, 0.49; 95% CI, 0.09-0.89; *P* = .02) and 91 children whose mothers had concentrations above the 30-ng/mL cutoff (adjusted MD, 0.37; 95% CI, 0.03-0.72; *P* = .04) (Table 4). No significant

Table 3. Association Between Vitamin D Supplementation Group and Psychiatric Symptoms^a

Measure	Comparison (95% CI) ^b	<i>P</i> value
CBCL score, MD		
Internalizing problems		
Model 1 ^c	-0.17 (-0.38 to 0.04)	.12
Model 2 ^d	-0.20 (-0.41 to 0.01)	.07
Externalizing problems		
Model 1 ^c	0.03 (-0.18 to 0.24)	.79
Model 2 ^d	0.01 (-0.21 to 0.22)	.94
Total problems		
Model 1 ^c	-0.04 (-0.25 to 0.17)	.71
Model 2 ^d	-0.08 (-0.29 to 0.14)	.48
Clinically significant problems, OR		
Internalizing problems		
Model 1 ^c	0.45 (0.20 to 0.98)	.05
Model 2 ^d	0.40 (0.17 to 0.94)	.04
Externalizing problems		
Model 1 ^c	1.08 (0.53 to 2.20)	.83
Model 2 ^d	0.89 (0.42 to 1.91)	.77
Total problems		
Model 1 ^c	1.07 (0.42 to 2.69)	.90
Model 2 ^d	0.81 (0.29 to 2.23)	.68

Abbreviations: CBCL, Childhood Behavior Checklist; MD, mean difference; OR, odds ratio.

^a Psychiatric symptoms were assessed at ages 6 to 8 years using the Childhood Behavior Checklist.

^b In linear models, raw scores were square root transformed owing to skewness and converted to Z scores (0 = mean; 1 = 1 SD). MDs were calculated comparing children in the 1200-IU supplementation group with those in the 400 IU supplementation group. Raw scores were converted to T scores and dichotomized at 64 or greater to reflect clinically significant problems. ORs and 95% CIs from logistic regression analyses show odds of belonging to a group with clinically significant problems for the 1200-IU supplementation group compared with the 400-IU supplementation group.

^c Unadjusted model.

^d Model adjusted for sex, season of birth, maternal depressive symptoms at birth (using Center for Epidemiological Studies Depression Scale, and parental single status at follow-up. In adjusted models, there were 155 children for the 400-IU group and 163 children for the 1200-IU group owing to missing Center for Epidemiological Studies Depression Scale data.

differences were found between 400-IU and 1200-IU groups in children whose mothers had 25(OH)D concentrations of 30 ng/mL or greater (eTable 7 in Supplement 2).

Discussion

In this secondary analysis of the VIDIRCT, we explored the potential impact of higher-than-standard vitamin D₃ supplementation between ages 2 weeks and 2 years on psychiatric symptoms at mean age 7.1 years. We found a 5.6% prevalence of clinically significant internalizing problems in children who received 1200-IU oral vitamin D₃ supplementation compared with 11.8% among those who received the standard recommended dose of 400 IU daily. No differences were found for total or externalizing problems. Although statistically significant differences at the *P* < .05 level were observed only for the dichotomous internalizing problems outcome, findings from the linear regression analysis followed the same direction, supporting the logistic regression findings.

Furthermore, internalizing problem scores were significantly higher for children from the 400-IU group with maternal 25(OH)D levels less than 30 ng/mL, compared with children from the 1200-IU group regardless of maternal 25(OH)D status. This should be interpreted cautiously, however, and be considered only as hypothesis generating given the absence of interactions between maternal 25(OH)D level and supplementation status.

Table 4. Association of Supplementation and Maternal Vitamin D Level Subgroup With Psychiatric Symptoms^a

Measure	Group 2 ^{b,c}		Group 3 ^{b,c}		Group 4 ^{b,c}	
	Comparison (95% CI) ^d	<i>P</i> value	Comparison (95% CI) ^d	<i>P</i> value	Comparison (95% CI) ^d	<i>P</i> value
CBCL score, MD						
Internalizing problems						
Model 1 ^e	-0.39 (-0.80 to 0.01)	.05	-0.32 (-0.67 to 0.02)	.07	-0.41 (-0.75 to -0.07)	.02
Model 2 ^f	-0.49 (-0.89 to -0.09)	.02	-0.30 (-0.66 to 0.05)	.10	-0.37 (-0.72 to -0.03)	.04
Externalizing problems						
Model 1 ^e	-0.12 (-0.53 to 0.29)	.56	-0.21 (-0.56 to 0.14)	.24	-0.07 (-0.41 to 0.28)	.71
Model 2 ^f	-0.12 (-0.54 to 0.29)	.56	-0.14 (-0.51 to 0.22)	.44	-0.02 (-0.38 to 0.34)	.91
Total problems						
Model 1 ^e	-0.32 (-0.72 to 0.08)	.12	-0.41 (-0.76 to -0.06)	.02	-0.31 (-0.65 to 0.03)	.08
Model 2 ^f	-0.34 (-0.75 to 0.06)	.10	-0.30 (-0.66 to 0.06)	.10	-0.23 (-0.58 to 0.12)	.19
Clinically significant problems, OR						
Internalizing problems						
Model 1 ^e	0.30 (0.08 to 1.20)	.09	0.47 (0.17 to 1.28)	.22	0.23 (0.07 to 0.73)	.01
Model 2 ^f	0.31 (0.07 to 1.31)	.11	0.50 (0.16 to 1.55)	.23	0.21 (0.06 to 0.78)	.02
Externalizing problems						
Model 1 ^e	0.49 (0.15 to 1.60)	.33	0.49 (0.15 to 1.60)	.24	0.97 (0.34 to 2.75)	.95
Model 2 ^f	0.28 (0.05 to 1.59)	.15	0.60 (0.17 to 2.19)	.44	1.02 (0.32 to 3.21)	.98
Total problems						
Model 1 ^e	0.39 (0.07 to 2.12)	.28	0.39 (0.10 to 1.53)	.18	0.56 (0.16 to 1.92)	.35
Model 2 ^f	0.19 (0.02 to 1.82)	.15	0.48 (0.11 to 2.12)	.34	0.53 (0.13 to 2.12)	.37

Abbreviations: ; CBCL, Childhood Behavior Checklist; MD, mean difference; OR, odds ratio.

^a Psychiatric symptoms were assessed at ages 6 to 8 years using the CBCL.

^b Groups 1 and 2 had maternal serum 25-hydroxyvitamin D (25[OH]D) levels less than 30 ng/mL (to convert to nanomoles per liter, multiply by 2.496), with child supplementation levels of 400-IU and 1200-IU vitamin D₃, respectively. Groups 3 and 4 had maternal 25(OH)D levels of 30 ng/mL or greater, with child supplementation levels of 400-IU and 1200-IU vitamin D₃, respectively.

^c Population numbers differ for model 1 vs model 2 analyses owing to missing data for the Center for Epidemiological Studies Depression Scale covariate (group 1: 49 vs 48 children; group 2: 47 vs 44 children; group 3: 94 vs 83 children; group 4: 101 vs 91 children).

^d In linear models, raw scores were square root transformed owing to skewness and converted to Z scores (0 = mean; 1 = 1SD). MDs were calculated compared with children in group 1. In logistic regression models, raw scores were converted to *T* scores and dichotomized at 64 or greater to reflect clinically significant problems. ORs and 95% CIs from logistic regression analyses show odds of belonging to a group with clinically significant problems for each subgroup compared with the same reference group as described previously (group 1).

^e Unadjusted model.

^f Model adjusted for sex, season of birth, maternal depressive symptoms at birth, and parental single status at follow-up.

Although previous studies^{6-9,13,33} have suggested that higher 25(OH)D levels during fetal life and early childhood may lower the risk of childhood psychopathology, to our knowledge, this is the first RCT to assess the potential impact of high-dose vitamin D₃ supplementation in healthy infants and up to age 2 years on psychiatric symptoms during late preschool and early school age. We previously studied this population up to age 2 years and found no evidence of systematic benefits in child neurodevelopment of higher-than-standard supplementation.¹⁰ Conversely, a potential increase in externalizing problems among children in the 1200-IU supplementation group could not fully be excluded. In this study, we found no differences in externalizing problems between groups.

The potential associations of maternal and childhood 25(OH)D levels with later neurodevelopmental and mental health outcomes were previously comprehensively summarized.^{6,7,34} Only a few studies, however, explored the potential association between childhood vitamin D levels and features of internalizing behaviors, such as depression. In a prospective birth cohort study⁸ among 2759 children, higher 25(OH)D concentrations at mean age 9.8 years were associated with lower levels of depressive symptoms at age 13.8 years but not age 10.6 years, suggesting a sustained beneficial outcome increasing over time. A prospective cohort study⁹ among 273 children found that those with 25(OH)D levels less than 30 ng/mL (10.3% of participants) at age 5 to 12 years had higher internalizing and externalizing scores after a median follow-up of 6 years. Conversely, a 2022 cross-sectional study³⁵ among 704 children and adolescents aged 11 to 16 years found no association between 25(OH)D concentration and depressive symptoms.

Studies focusing on maternal pregnancy 25(OH)D levels have reported inconsistent findings. A study³³ among 487 mother-child pairs found an inverse association between first-trimester 25(OH)D levels and externalizing but not internalizing symptoms. In a pregnancy cohort study among 743 mother-child pairs, no associations were found between maternal 25(OH)D concentrations at the 18th pregnancy week and total, internalizing, or externalizing symptoms measured in the child at ages 2, 5, 8, 10, 14, or 17 years.³⁶ In a study¹³ using data from VIDI and the Dutch Generation R cohort study (777 and 1505 mother-child pairs, respectively), lower early to midpregnancy 25(OH)D concentration was associated with higher infant negative affectivity. Negative affectivity is a temperament trait associated with increased risk for internalizing problems in childhood and adolescence.³⁷ Although inconclusive, our subgroup analysis findings may suggest that exposure to maternal 25OHD levels lower than 30 ng/mL during pregnancy combined with standard dose supplementation could increase the risk for later internalizing problems compared with receiving higher-than-standard supplementation during early childhood and may potentially partly explain earlier inconsistencies in the literature.

Strengths and Limitations

This study has several strengths, among them the double-blind RCT setting, standardized data collection, and well-characterized study population. Outcomes were assessed using CBCL, a widely used, validated questionnaire^{38,39} that allows for assessment of various aspects of childhood behavioral symptoms and potential emerging or manifest signs of psychopathology. CBCL was previously used in studies from Finland.^{40,41}

This study has several limitations as well. Of the original study population (987 families), 546 families (55.3%) remained in the 6 to 8-year follow-up study, and of these, 346 families (63.4%) completed the CBCL questionnaire. Baseline characteristics were somewhat more beneficial among the study population compared with those lost to follow-up, potentially limiting generalizability to a more diverse population. Furthermore, the proportion of children with maternal 25(OH)D levels less than 30 ng/mL was lower among study participants than in nonparticipants (33.0% vs 40.2%), influencing the number of children available for subgroup analyses. However, attrition rates were similar between supplementation groups, baseline characteristics for nonparticipants did not differ between groups, and inverse probability weighting estimation revealed no indication of attrition bias. Externalizing and internalizing behaviors at age 2 years did not differ between participants and

nonparticipants, suggesting that study participants were representative of the 2-year assessment participants in this regard.¹⁰

Questionnaires were collected from September 2020 to May 2021, concurrently with the global SARS-CoV-2 pandemic. The pandemic may have directly and indirectly negatively influenced mental health in children.^{42,43} We have no reason, however, to suspect that the burden of the pandemic would have differed between supplementation groups.

Since 2003, milk products and fat spreads in Finland have been fortified with vitamin D, resulting in improved population vitamin D levels.^{44,45} This may limit comparisons with studies performed in Finland before 2003 and with countries lacking systematic vitamin D fortification. Furthermore, whether our findings generalize to children living at other geographical latitudes needs to be investigated.

Conclusions

This secondary analysis of an RCT found that a higher-than-standard vitamin D₃ supplementation (1200 IU daily vs 400 IU) between ages 2 weeks and 2 years reduced the risk of internalizing problems later in childhood at ages 6 to 8 years. Results from the exploratory, post hoc subgroup analysis were inconclusive and need to be verified in future studies; further studies may suggest that early life higher-dose vitamin D₃ supplementation is associated with benefits for children exposed to lower pregnancy 25(OH)D levels. Furthermore, study findings need to be interpreted in context with outcomes related to children's somatic health (eg, growth and allergies), for which lower doses were found to be more beneficial during infancy^{20,46}; these findings also need to be repeated and assessed for general safety.

ARTICLE INFORMATION

Accepted for Publication: April 6, 2023.

Published: May 19, 2023. doi:10.1001/jamanetworkopen.2023.14319

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2023 Sandboge S et al. *JAMA Network Open*.

Corresponding Author: Samuel Sandboge, MD, PhD, Psychology/Welfare Sciences, Faculty of Social Sciences, University of Tampere, Kalevantie 4, 33100 Tampere, Finland (samuel.sandboge@tuni.fi).

Author Affiliations: Psychology/Welfare Sciences, Faculty of Social Sciences, University of Tampere, Tampere, Finland (Sandboge, Heinonen); Population Health Unit, Finnish Institute for Health and Welfare, Helsinki, Finland (Sandboge, Lahti-Pulkkinen, Hauta-alus, Kajantie); Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland (Räikkönen, Lahti-Pulkkinen, Girchenko, Heinonen); Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (Lahti-Pulkkinen); Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland (Hauta-alus, Holmlund-Suila, Kajantie, Mäkitie, Andersson); Research Unit for Pediatrics, Dermatology, Clinical Genetics, Obstetrics and Gynecology, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Hauta-alus, Kajantie); Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland (Hauta-alus, Holmlund-Suila, Mäkitie); Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (Kajantie); Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland (Mäkitie); Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden (Mäkitie); Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden (Mäkitie); Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada (Heinonen).

Author Contributions: Drs Sandboge and Heinonen had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Sandboge, Räikkönen, Mäkitie, Andersson, Heinonen.

Acquisition, analysis, or interpretation of data: Sandboge, Räikkönen, Lahti-Pulkkinen, Hauta-alus, Holmlund-Suila, Girchenko, Kajantie, Andersson, Heinonen.

Drafting of the manuscript: Sandbøge.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Sandbøge, Lahti-Pulkkinen, Girchenko, Heinonen.

Obtained funding: Rääkkönen, Hauta-alus, Mäkitie, Andersson, Heinonen.

Administrative, technical, or material support: Hauta-alus, Holmlund-Suila.

Supervision: Kajantie, Mäkitie, Andersson, Heinonen.

Conflict of Interest Disclosures: Dr Kajantie reported receiving grants from the Novo Nordisk Foundation outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by the Academy of Finland, Sigrid Jusélius Foundation, Signe and Ane Gyllenberg Foundation, Finland Foundation for Pediatric Research, Yrjö Jahnsson Foundation, Novo Nordisk Foundation, Finska Läkaresällskapet, Finland Special Governmental Subsidy for Clinical Research, Juho Vainio Foundation, and Päivikki and Sakari Sohlberg Foundation. Orion Pharmaceuticals is acknowledged for providing vitamin D₃ supplements gratis for the study.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 3.

Additional Contributions: We would like to express our sincerest gratitude to all children and families who participated in the study. We would also like to thank Jenni Rosendahl, MD, PhD; Otto Helve, MD, PhD; Saara Valkama, MD; and Maria Enlund-Cerullo, MD, and research nurses Nea Boman, BA; Sirpa Nolvi, BA; Rhea Paajanen, BA; and Päivi Turunen, BA (Helsinki Children's Hospital), for their assistance in data collection and laboratory technician Sari Lindén, BA (Helsinki Children's Hospital), for work on this study. These contributors have been compensated with salary payments for this work.

REFERENCES

1. Nair R, Maseeh A. Vitamin D: the "sunshine" vitamin. *J Pharmacol Pharmacother*. 2012;3(2):118-126.
2. Holick MF. Vitamin D deficiency. *N Engl J Med*. 2007;357(3):266-281. doi:10.1056/NEJMra070553
3. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. *J Chem Neuroanat*. 2005;29(1):21-30. doi:10.1016/j.jchemneu.2004.08.006
4. Eyles DW, Feron F, Cui X, et al. Developmental vitamin D deficiency causes abnormal brain development. *Psychoneuroendocrinology*. 2009;34(suppl 1):S247-S257. doi:10.1016/j.psyneuen.2009.04.015
5. Barican JL, Yung D, Schwartz C, Zheng Y, Georgiades K, Waddell C. Prevalence of childhood mental disorders in high-income countries: a systematic review and meta-analysis to inform policymaking. *Evid Based Ment Health*. 2022;25(1):36-44. doi:10.1136/ebmental-2021-300277
6. Föcker M, Antel J, Ring S, et al. Vitamin D and mental health in children and adolescents. *Eur Child Adolesc Psychiatry*. 2017;26(9):1043-1066. doi:10.1007/s00787-017-0949-3
7. Khoshbakht Y, Bidaki R, Salehi-Abargouei A. Vitamin D status and attention deficit hyperactivity disorder: a systematic review and meta-analysis of observational studies. *Adv Nutr*. 2018;9(1):9-20. doi:10.1093/advances/nmx002
8. Tolppanen AM, Sayers A, Fraser WD, Lewis G, Zammit S, Lawlor DA. The association of serum 25-hydroxyvitamin D3 and D2 with depressive symptoms in childhood—a prospective cohort study. *J Child Psychol Psychiatry*. 2012;53(7):757-766. doi:10.1111/j.1469-7610.2011.02518.x
9. Robinson SL, Marín C, Oliveros H, Mora-Plazas M, Lozoff B, Villamor E. Vitamin D deficiency in middle childhood is related to behavior problems in adolescence. *J Nutr*. 2020;150(1):140-148. doi:10.1093/jn/nxz185
10. Tuovinen S, Rääkkönen K, Holmlund-Suila E, et al. Effect of high-dose vs standard-dose vitamin D supplementation on neurodevelopment of healthy term infants: a randomized clinical trial. *JAMA Netw Open*. 2021;4(9):e2124493. doi:10.1001/jamanetworkopen.2021.24493
11. Solmi M, Radua J, Olivola M, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. *Mol Psychiatry*. 2022;27(1):281-295. doi:10.1038/s41380-021-01161-7
12. Teffer K, Semendeferi K. Human prefrontal cortex: evolution, development, and pathology. *Prog Brain Res*. 2012;195:191-218. doi:10.1016/B978-0-444-53860-4.00009-X
13. Sammallahti S, Holmlund-Suila E, Zou R, et al. Prenatal maternal and cord blood vitamin D concentrations and negative affectivity in infancy. *Eur Child Adolesc Psychiatry*. Published online October 18, 2021. doi:10.1007/s00787-021-01894-4

14. Morales E, Julvez J, Torrent M, et al. Vitamin D in pregnancy and attention deficit hyperactivity disorder-like symptoms in childhood. *Epidemiology*. 2015;26(4):458-465. doi:10.1097/EDE.0000000000000292
15. Sucksdorff M, Brown AS, Chudal R, et al. Maternal vitamin D levels and the risk of offspring attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 2021;60(1):142-151.e2. doi:10.1016/j.jaac.2019.11.021
16. Lee BK, Eyles DW, Magnusson C, et al. Developmental vitamin D and autism spectrum disorders: findings from the Stockholm Youth Cohort. *Mol Psychiatry*. 2021;26(5):1578-1588. doi:10.1038/s41380-019-0578-y
17. Strøm M, Halldorsson TI, Hansen S, et al. Vitamin D measured in maternal serum and offspring neurodevelopmental outcomes: a prospective study with long-term follow-up. *Ann Nutr Metab*. 2014;64(3-4):254-261. doi:10.1159/000365030
18. Rosendahl J, Valkama S, Holmlund-Suila E, et al. Effect of higher vs standard dosage of vitamin D₃ supplementation on bone strength and infection in healthy infants: a randomized clinical trial. *JAMA Pediatr*. 2018;172(7):646-654. doi:10.1001/jamapediatrics.2018.0602
19. Helve O, Viljakainen H, Holmlund-Suila E, et al. Towards evidence-based vitamin D supplementation in infants: vitamin D intervention in infants (VIDI)—study design and methods of a randomised controlled double-blinded intervention study. *BMC Pediatr*. 2017;17(1):91. doi:10.1186/s12887-017-0845-5
20. Hauta-Alus HH, Holmlund-Suila EM, Kajantie E, et al. The effects of vitamin D supplementation during infancy on growth during the first 2 years of life. *J Clin Endocrinol Metab*. 2021;106(3):e1140-e1155. doi:10.1210/clinem/dgaa943
21. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96(7):1911-1930. doi:10.1210/jc.2011-0385
22. Achenbach T. Manual for the child behavior checklist/4-18 and 1991 profile. University of Vermont Department of Psychiatry. Accessed October 9, 2022. <https://cir.nii.ac.jp/crid/1570009749384841472>
23. McEwen BS, Milner TA. Understanding the broad influence of sex hormones and sex differences in the brain. *J Neurosci Res*. 2017;95(1-2):24-39. doi:10.1002/jnr.23809
24. Asano R, Tsuchiya KJ, Harada T, et al; for Hamamatsu Birth Cohort (HBC) Study Team. Season of birth predicts emotional and behavioral regulation in 18-month-old infants: Hamamatsu Birth Cohort for Mothers and Children (HBC Study). *Front Public Health*. 2016;4:152. doi:10.3389/fpubh.2016.00152
25. Bai Y, Shang G, Wang L, Sun Y, Osborn A, Rozelle S. The relationship between birth season and early childhood development: evidence from northwest rural China. *PLoS One*. 2018;13(10):e0205281. doi:10.1371/journal.pone.0205281
26. Pierrat V, Marchand-Martin L, Arnaud C, et al; EPIPAGE-2 writing group. Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks' gestation in France in 2011: EPIPAGE-2 cohort study. *BMJ*. 2017;358:j3448. doi:10.1136/bmj.j3448
27. Tearne JE. Older maternal age and child behavioral and cognitive outcomes: a review of the literature. *Fertil Steril*. 2015;103(6):1381-1391. doi:10.1016/j.fertnstert.2015.04.027
28. Darmawikarta D, Chen Y, Lebovic G, Birken CS, Parkin PC, Maguire JL. Total duration of breastfeeding, vitamin D supplementation, and serum levels of 25-hydroxyvitamin D. *Am J Public Health*. 2016;106(4):714-719. doi:10.2105/AJPH.2015.303021
29. Bradley RH, Corwyn RF. Socioeconomic status and child development. *Annu Rev Psychol*. 2002;53:371-399. doi:10.1146/annurev.psych.53.100901.135233
30. Daryanani I, Hamilton JL, Abramson LY, Alloy LB. Single mother parenting and adolescent psychopathology. *J Abnorm Child Psychol*. 2016;44(7):1411-1423. doi:10.1007/s10802-016-0128-x
31. Polańska K, Jurewicz J, Hanke W. Smoking and alcohol drinking during pregnancy as the risk factors for poor child neurodevelopment—a review of epidemiological studies. *Int J Occup Med Environ Health*. 2015;28(3):419-443. doi:10.13075/ijomeh.1896.00424
32. Tuovinen S, Lahti-Pulkkinen M, Girchenko P, et al. Maternal depressive symptoms during and after pregnancy and child developmental milestones. *Depress Anxiety*. 2018;35(8):732-741. doi:10.1002/da.22756
33. Daraki V, Roumeliotaki T, Koutra K, et al. High maternal vitamin D levels in early pregnancy may protect against behavioral difficulties at preschool age: the Rhea mother-child cohort, Crete, Greece. *Eur Child Adolesc Psychiatry*. 2018;27(1):79-88. doi:10.1007/s00787-017-1023-x
34. Mutua AM, Mogire RM, Elliott AM, et al. Effects of vitamin D deficiency on neurobehavioural outcomes in children: a systematic review. *Wellcome Open Res*. 2020;5:28. doi:10.12688/wellcomeopenres.15730.1

35. Al-Sabah R, Al-Taiar A, Shaban L, Albatineh AN, Sharaf Alddin R, Durgampudi PK. Vitamin D level in relation to depression symptoms during adolescence. *Child Adolesc Psychiatry Ment Health*. 2022;16(1):53. doi:10.1186/s13034-022-00489-4
36. Whitehouse AJO, Holt BJ, Serralha M, Holt PG, Kusel MMH, Hart PH. Maternal serum vitamin D levels during pregnancy and offspring neurocognitive development. *Pediatrics*. 2012;129(3):485-493. doi:10.1542/peds.2011-2644
37. Kostyrka-Allchorne K, Wass SV, Sonuga-Barke EJS. Research review: do parent ratings of infant negative emotionality and self-regulation predict psychopathology in childhood and adolescence: a systematic review and meta-analysis of prospective longitudinal studies. *J Child Psychol Psychiatry*. 2020;61(4):401-416. doi:10.1111/jcpp.13144
38. Crijnen AA, Achenbach TM, Verhulst FC. Comparisons of problems reported by parents of children in 12 cultures: total problems, externalizing, and internalizing. *J Am Acad Child Adolesc Psychiatry*. 1997;36(9):1269-1277. doi:10.1097/00004583-199709000-00020
39. Nøvik TS. Validity of the Child Behaviour Checklist in a Norwegian sample. *Eur Child Adolesc Psychiatry*. 1999;8(4):247-254. doi:10.1007/s007870050098
40. Koskentausta T, Iivainen M, Almqvist F. CBCL in the assessment of psychopathology in Finnish children with intellectual disability. *Res Dev Disabil*. 2004;25(4):341-354. doi:10.1016/j.ridd.2003.12.001
41. Teivaanmäki S, Huhdanpää H, Kiuru N, Aronen ET, Närhi V, Klenberg L. Heterogeneity of executive functions among preschool children with psychiatric symptoms. *Eur Child Adolesc Psychiatry*. 2020;29(9):1237-1249. doi:10.1007/s00787-019-01437-y
42. Oliveira JMD, Butini L, Pauletto P, et al. Mental health effects prevalence in children and adolescents during the COVID-19 pandemic: a systematic review. *Worldviews Evid Based Nurs*. 2022;19(2):130-137. doi:10.1111/wvn.12566
43. Kauhanen L, Wan Mohd Yunus WMA, Lempinen L, et al. A systematic review of the mental health changes of children and young people before and during the COVID-19 pandemic. *Eur Child Adolesc Psychiatry*. Published online August 12, 2022. doi:10.1007/s00787-022-02060-0
44. Jääskeläinen T, Itkonen ST, Lundqvist A, et al. The positive impact of general vitamin D food fortification policy on vitamin D status in a representative adult Finnish population: evidence from an 11-y follow-up based on standardized 25-hydroxyvitamin D data. *Am J Clin Nutr*. 2017;105(6):1512-1520. doi:10.3945/ajcn.116.151415
45. Hauta-Alus HH, Korkalo L, Holmlund-Suila EM, et al. Food and nutrient intake and nutrient sources in 1-year-old infants in Finland: a cross-sectional analysis. *Nutrients*. 2017;9(12):1309. doi:10.3390/nu9121309
46. Rosendahl J, Pelkonen AS, Helve O, et al. High-dose vitamin D supplementation does not prevent allergic sensitization of infants. *J Pediatr*. 2019;209:139-145.e1. doi:10.1016/j.jpeds.2019.02.021

SUPPLEMENT 1.

Trial Protocol and Statistical Analysis Plan

SUPPLEMENT 2.

eAppendix. Supplementary Methods

eReferences.

eTable 1. Attrition Table for Participants vs Nonparticipants

eTable 2. Associations Between Covariates and Child Behavior Checklist Scores

eTable 3. Study Participant Characteristics by Sex

eTable 4. Child Psychiatric Symptoms and Problems by Sex

eTable 5. Associations Between Vitamin D₃ Concentrations at Ages 1 and 2 y and Psychiatric Symptoms at Ages 6 to 8 y

eTable 6. Prevalence of Child Behavior Checklist T Scores within the Clinical Range for Maternal Vitamin D₃ and Supplementation Status Subgroups

eTable 7. Association of Subgroups by Vitamin D₃ Supplementation and Maternal Vitamin D₃ Level With Psychiatric Symptoms at Ages 6 to 8 y

eFigure. Distribution of Raw Internalizing, Externalizing, and Total Problems Sum Scores by Supplementation Group

SUPPLEMENT 3.

Data Sharing Statement